29
/
en
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
2135682
178559
2

jun 1, 2018 - FDA sent safety labeling change notification letters to drug companies with approved opioid analgesic products intended for use in an outpatient setting, which require the companies to include new safety information regarding the Opioid Analgesic REMS in the Boxed Warning and Warnings and Precautions sections of prescribing information due to a general lack of awareness of the REMS among all opioid analgesic prescribers.

Added to timeline:

13 Nov 2018
0
0
313
Opioids and the FDA

Date:

jun 1, 2018
Now
~ 5 years and 9 months ago
PremiumAbout & FeedbackTermsPrivacy
logo
© 2022 Selected Technologies LLC – Morgan Hill, California